Molecular characterization of moxifloxacin resistance from Canadian Clostridium difficile clinical isolates

Diagnostic Microbiology and Infectious Disease

Volumn 66, Issue 4, 2010, Pages 419-424

  Walkty, Andrew ^a   Boyd, David A ^a   Gravel, Denise ^b   Hutchinson, Jim ^c   McGeer, Allison ^d   Moore, Dorothy ^e   Simor, Andrew ^f   Suh, Kathryn ^g   Taylor, Geoff ^h   Miller, Mark ⁱ   Mulvey, Michael R ^a  

^a PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^b PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^c Health Sciences Centre St John's   (Canada)

^d MOUNT SINAI HOSPITAL   (Canada)

^e MONTREAL CHILDREN S HOSPITAL   (Canada)

^f SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^g UNIVERSITY OF OTTAWA   (Canada)

^h UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

ⁱ MCGILL UNIVERSITY   (Canada)

Author keywords

Clostridium difficile; GyrA; GyrB; Moxifloxacin resistance

Indexed keywords

CIPROFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING) A; DNA TOPOISOMERASE (ATP HYDROLYSING) B; GATIFLOXACIN; ISOLEUCINE; MOXIFLOXACIN; THREONINE;

AMINO ACID SUBSTITUTION; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CANADA; CLOSTRIDIUM DIFFICILE; CONTROLLED STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PULSED FIELD GEL ELECTROPHORESIS; SEQUENCE ANALYSIS;

AMINO ACID SUBSTITUTION; ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; BACTERIAL PROTEINS; BACTERIAL TYPING TECHNIQUES; CANADA; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; DNA FINGERPRINTING; DNA GYRASE; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, BACTERIAL; ELECTROPHORESIS, GEL, PULSED-FIELD; MICROBIAL SENSITIVITY TESTS; MUTATION, MISSENSE; POLYMERASE CHAIN REACTION; QUINOLINES; SEQUENCE ANALYSIS, DNA;

EID: 77649311335     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2009.12.002     Document Type: Article

References (15)

1. Ackermann G., Tang Y.J., Kueper R., Heisig P., Rodloff A.C., Silva Jr. J., and Cohen S.H. Resistance to moxifloxacin in toxigenic Clostridium difficile isolates is associated with mutations in gyrA. Antimicrob. Agents Chemother. 45 (2001) 2348-2353
2. Bourgault A.M., Lamothe F., Loo V.G., Poirier L., and the CDAD-CSI Study Group. In vitro susceptibility of Clostridium difficile clinical isolates from a multi-institutional outbreak in southern Quebec, Canada. Antimicrob. Agents Chemother. 50 (2006) 3473-3475
3. Clinical and Laboratory Standards Institute (CLSI). Methods for antimicrobial susceptibility testing of anaerobic bacteria; approved standard-seventh edition, M11-A7 (2007), CLSI, Wayne, PA
4. Dridi L., Tankovic J., Burghoffer B., Barbut F., and Petit J.C. gyrA and gyrB mutations are implicated in cross-resistance to ciprofloxacin and moxifloxacin in Clostridium difficile. Antimicrob. Agents Chemother. 46 (2002) 3418-3421
5. Drudy D., Quinn T., O'Mahony R., Kyne L., O'Gaora P., and Fanning S. High-level resistance to moxifloxacin and gatifloxacin associated with a novel mutation in gyrB in toxin-A-negative, toxin-B-positive Clostridium difficile. J. Antimicrob. Chemother. 58 (2006) 1264-1267
6. Drudy D., Kyne L., O'Mahony R., and Fanning S. gyrA mutations in fluoroquinolone resistant Clostridium difficile PCR-027. Emerg. Infect. Dis. 13 (2007) 504-505
7. Gravel D., Miller M., Simor A., Taylor G., Gardam M., McGeer A., Hutchinson J., Moore D., Kelly S., Boyd D., Mulvey M., and the Canadian Nosocomial Infection Surveillance Program. Health care-associated Clostridium difficile infection in adults admitted to acute care hospitals in Canada: a Canadian Nosocomial Infection Surveillance Program Study. Clin. Infect. Dis. 48 (2009) 568-576
8. Kelly C.P., and LaMont J.T. Clostridium difficile-more difficult than ever. N. Engl. J. Med. 359 (2008) 1932-1940
9. Loo V.G., Poirier L., Miller M.A., Oughton M., Libman M.D., Michaud S., Bourgault A.M., Nguyen T., Frenette C., Kelly M., Vibien A., Brassard P., Fenn S., Dewar K., Hudson T.J., Horn R., René P., Monczak Y., and Dascal A. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N. Engl. J. Med. 353 (2005) 2442-2449
10. McCusker M.E., Harris A.D., Perencevich E., and Roghmann M.C. Fluoroquinolone use and Clostridium difficile-associated diarrhea. Emerg. Infect. Dis. 9 (2003) 730-733
11. Miller M., Gravel D., Mulvey M., Taylor G., Boyd D., Simor A., Gardam M., McGeer A., Hutchinson J., Moore D., Kelly S., and the Canadian Nosocomial Infection Surveillance Program (CNISP). Hospital-acquired Clostridium difficile infection in Canada: patient age and infecting strain type are highly predictive of severe outcome and mortality. Clin. Infect. Dis. (2010). http://www.journals.uchicago.edu/doi/full/10.1086/648678 (in press). Available at: http://www.journals.uchicago.edu/doi/full/10.1086/648678. Accessed February 17, 2010
12. Owens R.C., Donskey C.J., Gaynes R.P., Loo V.G., and Muto C.A. Antimicrobial-associated risk factors for Clostridium difficile infection. Clin. Infect. Dis. 46 (2008) S19-S31
13. Pépin J., Saheb N., Coulombe M.A., Alary M.E., Corriveau M.P., Authier S., Leblanc M., Rivard G., Bettez M., Primeau V., Nguyen M., Jacob C.E., and Lanthier L. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin. Infect. Dis. 41 (2005) 1254-1260
14. Spigaglia P., Barbanti F., Mastrantonio P., Brazier J.S., Barbut F., Delmee M., Kuijpur E., Poxton I.R., and on behalf of the European Study Group on Clostridium difficile (ESGCD). Fluoroquinolone resistance in Clostridium difficile isolates from a prospective study of C. difficile infections in Europe. J. Med. Microbiol. 57 (2008) 784-789
15. Zhanel G.G., Walkty A., Vercaigne L., Karlowsky J.A., Embil J., Gin A.S., and Hoban D.J. The new fluoroquinolones: a critical review. Can. J. Infect. Dis. 10 (1999) 207-238